

CURRICULUM VITAE

Date of Revision: June 30, 2021

Name: Simon Peter Kim, M.D., M.P.H.

School: University of Colorado School of Medicine

Education:

BA University of Rochester, Rochester, New York, 1991-1995

M.P.H. University of Illinois, Chicago, Illinois, 1995-1997

M.D. Chicago Medical School, North Chicago, IL, 2000-2004

Career/Academic Appointments:2014

July 1997 – June 1999 Research Analyst, Northwestern University, Chicago, Illinois
July 2004 – June 2010 Urology Resident, University of Michigan, Ann Arbor, Michigan
July 2010 – June 2012 Research Scholar in the Healthcare Delivery and Research Program, Mayo Clinic, Rochester, Minnesota
July 2010 – June 2013 Urologic Oncology Fellow, Clinical Instructor in Urology, Mayo Clinic, Rochester, Minnesota
July 2013 – July 2014 Assistant Professor, Yale University, New Haven, Connecticut
August 2014 – June 2017 Assistant Professor, Case Western Reserve University School of Medicine, Department of Urology, Cleveland, Ohio
June 2017 – January 2019 Associate Professor, Case Western Reserve University School of Medicine, Department of Urology, Cleveland, Ohio
February 2019 – present Associate Professor, University of Colorado Denver, Division of Urology, Aurora, Colorado

Professional Appointments:

November 2014 – Jan 2019 Co-director, Center for Quality and Outcomes, Urology Institute, Cleveland, Ohio
June 2017 – January 2019 Director of Robotic Surgery, University Hospitals Cleveland Medical Center, Urology Institute, Cleveland, Ohio
June 2017 – January 2019 Director of Kidney and Bladder Cancer, University Hospitals Cleveland Medical Center, Urology Institute, Cleveland, Ohio
February 2019—present Member, Surgical Quality Improvement and Safety Committee, University of Colorado Denver, Aurora, Colorado
April 2019 – present Cancer Center Member, University of Colorado Cancer, Aurora, Colorado
April 2019 – present Associate Residency Program Director, University of Colorado Denver, Aurora, Colorado
June 2019 – present Site Director, University of Colorado Denver Hospital, Aurora, Colorado

Board Certification:

2016 Board certified, American Board of Urology (ABU)
2013 Board certified, Society of Urologic Oncology (SUO)

Professional Honors & Recognition

National

2013 The Journal of Urology Best Reviewer in 2013 Award
2011 Best poster, North Central Section of the AUA: The impact of squamous cell histology on clinicopathologic characteristics and survival in patients undergoing radical cystectomy for bladder cancer
2004 Alpha Omega Alpha Chicago Medical School
1995 High Distinction in Health and Society University of Rochester, Rochester

Local

2021 Faculty Teaching Award, University of Colorado, Division of Urology
2005 Bronze Beeper—Excellence in Teaching, University of Michigan Medical School
2004 Board of Trustees Scholarship Award, Rosalind Franklin Medical School
2004 Alpha Omega Alpha Rosalind Franklin Medical School
1995 Cum Laude University of Rochester

Current Grants

Agency: National Institute of Health
I.D.# MD12-003
Funding Mechanism: R01
Title: “Testing in and out-of-visit decision aids for minority men with prostate cancer”
Role: Co-Principal Investigator
Percent effort: 20%
Total costs for project period: \$1,628,499
Project period: 9/2014 – 03/2021

Past Grants

Agency: Conquer Cancer Foundation/American Society of Clinical Oncology
I.D.# N/A
Funding Mechanism: Career Development Award
Title: “National trends in active surveillance for prostate cancer and understanding barriers to its use”
Role: Principal Investigator
Percent Effort: 30%
Total costs for project period: \$200,000
Project period: 07/2014-07/2017

Agency: Foundation for Informed Medical Decision-Making
I.D.# N/A
Title: “A national survey of urologists and radiation oncologists on prostate cancer and shared-decision making”
Role: Principal Investigator
Percent effort: 20%
Total costs for project period: \$25,000 per year
Project period: 10/2010-9/2011

Invited Speaking Engagements, Presentations, Symposia & Workshops: International/National

- 2020: South Central AUA Invited Speaker: Management of small renal masses, Austin Texas
- 2020: Rocky Mountain Urological Society: Quality of care for kidney cancer, Denver, CO
- 2020: Rocky Mountain Urological Society: Pro and Cons for partial or radical nephrectomy Denver, CO
- 2020: AUA Moderator, Localized Prostate Cancer Podium Session, Chicago, IL
- 2019: AUA Plenary Take Home Message—Outcomes Research, Chicago, IL
- 2019: AUA Moderator, Localized Prostate Cancer Poster Session, Chicago, IL
- 2019: Fox 31 News, “Prostate Cancer.” Denver, Colorado
- 2019: Rocky Mountain Urology Society: Challenging cases in bladder cancer
- 2018: AUA Abstract, “National trends of active surveillance for localized prostate cancer.” San Francisco, CA
- 2018: AUA Moderator, Localized Prostate Cancer Poster Session, San Francisco, CA
- 2017: Panelist, Case Comprehensive Cancer Center, 1st Annual Cancer Disparities Symposium “Building Bridges to Address Cancer Disparities.” Cleveland, OH
- 2016: AUA Moderator, Localized Prostate Cancer Poster Session, San Diego, CA
- 2015: Moderator, North Central Section of the American Urological Association, 89th Annual Meeting, Health Policy and Outcomes. Amelia, FL
- 2013: Kidney Cancer Association “Localized and Locally Advanced Renal Cell Carcinoma.” Chicago, IL
- 2012: ASCO Conference “A national survey of radiation oncologists and urologists on active surveillance for low-risk prostate cancer.” Chicago, IL
- 2012: AUA Conference “Risk factors and outcomes of urethral recurrence following radical cystectomy.” Atlanta, GA
- 2011: AUA Conference. “Determinants of long-term renal function for patients undergoing radical cystectomy with urinary diversion.” Washington, DC
- 2011: AUA Conference “Predictors and outcomes of late recurrence from renal cell carcinoma following surgical resection.” Washington, DC
- 2010: Kidney Cancer Association “Metastatic Kidney Cancer.” Chicago, IL
- 2008: AUA Conference “Accuracy of claims data to identify incident cases of benign prostatic hyperplasia.” Atlanta, GA
- 2008: AUA Conference “Quality of care among men with newly diagnosed benign prostatic hyperplasia and lower urinary tract symptoms in a managed care setting.” Atlanta, GA
- 2008: AUA Conference: “Clinical low risk prostate cancer: what can we tell patients at diagnosis.” Atlanta, GA
- 2008: AUA Conference “Emotional and role functioning are short lived for metastatic prostate cancer patients following castration.” Atlanta, GA
- 1999: ASCO Conference “The European Organization and Research for the Treatment of Cancer (EORTC): A reliable measure of disease progression.” Chicago, IL

Professional Services:

Professional Service for Professional Organizations:

- 2021-present Committee Member, Hispanic Cancer Outreach Committee, University of Colorado Cancer Center
- 2021-present Committee Member, AUA Research Diversity, Equity, and Inclusion Workgroup
- 2020-present Workgroup leader USMART Academy, American Urological Association (AUA)
- 2019-present Committee Member, Research Grants & Investigative Support Committee, American Urological Association (AUA)

2019 Grant reviewer, Study Section, National Cancer Institute (Program Project Applications (PAR-20-077))
2019-present Member, Society of Academic Urology
2015-Present Member, Society of Urologic Oncology (SUO)
2015-2019 Panel Member, National Comprehensive Cancer Network, Prostate Cancer Early Detection Clinical Practice Guidelines
2009-Present Member, European Urological Association (EUA)
2004-Present Diplomat, American Urological Association (AUA)
2004-Present Member, American College of Surgeons
2005-Present Member, American College of Physicians/American Society of Internal Medicine
2000-Present Member, American Medical Association

Journal Services:

Editorial Board

2019-present AME Medical Journal

Assistant Editor

2018-present Journal of Urology

Guest Editor

2020-present Cancer Medicine

Guest Editor

2020-2021 AME Medical Journal

Reviewer

2020-present The Prostate
2019-present The American Journal of Managed Care
2019-present European Urology Oncology
2019-present Cancer Epidemiology
2018-present European Urology Oncology
2018-present European Urology Focus
2017-present Annals of Epidemiology
2017-present Annals of Surgical Oncology
2017-present JAMA
2017-present Cancer Investigation
2017-present BMJ
2016-present American Urological Association (Abstracts)
2016-present PLOS One
2014-Present British Medical Journal
2014-Present European Urology
2014-Present Journal of Clinical Oncology
2014-Present Cancer
2014-Present Mayo Clinic Proceedings
2014-Present International Journal of Urology
2014-Present Frontiers in Genitourinary Oncology
2014-Present EJSO – the Journal of Cancer Surgery
2013-Present Journal of Oncology Practice
2013-Present Cancer Medicine
2013-Present JAMA Internal Medicine

2013-Present	JAMA Surgery
2012-present	Medical Decision Making
2012-present	British Journal of Urology International
2012-present	Urology
2010-present	British Journal of Cancer
2009-present	Urologic Oncology: Seminars and Original Investigations
2008-present	Journal of Urology

Bibliography

Peer-Reviewed Original Research

1. **Kim SP**, Bennett CL, Chan C, Chmiel J, Falcone D, Knight SJ, Kuzel T, Davis TC, Elstein AS, Moran E, Roberston CN, Smith JS. Quality of life and outcomes research in prostate cancer patients with low socioeconomic status. *Oncology*, 1999 Jun;13(6):823-32.
2. **Kim SP**, Knight SJ, Tomori C, Colella KM, Schoor RA, Shih L, Kuzel TM, Nadler RB, Bennett CL. Health literacy and shared decision making for prostate cancer patients with low socioeconomic status. *Cancer Investigation* 2001; 19(7):684-91.
3. Bennett CL, Price DK, **Kim SP**, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. *Journal of Clinical Oncology* 2002; 20(17):3599-604.
4. Talamonti MS, **Kim SP**, Yao KA, Wayne JD, Feinglass J, Bennett CL, Rao S. Surgical outcomes of patients with gastric carcinoma: The importance of primary tumor location and microvessel invasion. *Surgery* 2003;134(4):720-7.
5. **Kim SP**, Feinglass J, Bennett CL, Lyons T, Simon C, Weinberg MN, Talamonti MS. Merging claims data bases with a tumor registry to evaluate variations in cancer mortality: Results from a pilot study of 698 colorectal cancer patients treated at one hospital in the 1990s. *Cancer Investigation* 2005;22(2):225-33.
6. Rosevear HM, **Kim SP**, Faerber G, Roberts WW, Wolf JS. Retrograde ureteral stents for extrinsic ureteral obstruction: A nine-year experience at University of Michigan. *Urology* 2007;70(5):846-50
7. Wenzler DL, **Kim SP**, Faerber G, Roberts WW, Wolf JS. Success of ureteral stents for intrinsic ureteral obstruction. *Journal of Endourology* 2008;22(2):295-300.
8. **Kim SP**, Sarmast Z, Daignault S, Faerber GJ, McGuire EJ, Latini JM. Long term durability and functional outcomes among patients with artificial urinary sphincters: A 10-year retrospective review from the University of Michigan. *Journal of Urology* 2008;179:1912-16.
9. **Kim SP**, Labo J, Hollenbeck BK, Wood DP. Feasibility and safety of robotic assisted salvage prostatectomy for recurrent prostate cancer following radiation. *Journal of Robotic Surgery* 2008;2:81-3.
10. Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Skolarus TA, **Kim SP**, Montie JE, Miller DC. Delay in Diagnosis and bladder cancer mortality. *Cancer* 2010;116:5235-42.
11. Hollingsworth JM, Hollenbeck BK, Daignault S, **Kim SP**, Wei JT. Differences in the initial benign prostatic hyperplasia management between primary care physicians and urologists. *Urology* 2011;182(5):2410-4.
12. **Kim SP**, Angela AA, Weight CJ, Costello BA, Cheville JC, Lohse C, Allmer C, Leibovich BC. Independent validation of the 2010 American Joint Committee on Cancer TNM Classification for renal cell carcinoma: Results from a large, single institution cohort. *Journal of Urology*, 2011; 185(6):2035-9.
13. Weight CJ, **Kim SP**, Lohse CM, Cheville JC, Thompson RH, Boorjian SA, Leibovich BC. Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic

benefit and places a significant portion of patients at risk for asynchronous metastasis in a solitary adrenal gland. *European Urology* 2011;185(6):458-64.

14. Weight CJ, Atwell TD, Fazzio RT, **Kim SP**, Kenny L, Lohse CM, Boorjian SA, Leibovich BC, Thompson RH. A multidisciplinary evaluation of inter-reviewer agreement of the nephrometry score and the prediction of long-term outcomes. *Journal of Urology* 2011;186(4):1223-8.
15. **Kim SP**, Shah ND, Weight CJ, Thompson RH, Moriarty JP, Shippee ND, Costello BA, Boorjian SA, Leibovich BC. Contemporary trends in nephrectomy for renal cell carcinoma in the United States: Results from a population-based cohort. *Journal of Urology* 2011;186(5):779-85.
16. **Kim SP**, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, Lohse CM, Boorjian SA. Outcomes and clinicopathologic variables associated with late recurrence following nephrectomy for localized renal cell carcinoma. *Urology* 2011;78(5):1101-6.
17. Boorjian SA, **Kim SP**, Cheville JC, Weight CJ, Prabin T, Frank I. Clinicopathologic characteristics of urethral recurrence following radical cystectomy. *European Urology* 2011;60(6):1266-72.
18. **Kim SP**, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA. The implications of hospital-acquired adverse events on in-hospital mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. *Journal of Urology* 2012;187:2011-7.
19. Nabhan M, **Kim SP**, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of post-treatment PSA surveillance and prostate cancer outcomes: Results from a population-based cohort. *Mayo Clinic Proceedings* 2012;87(6):540-7.
20. **Kim SP**, Thompson RH, Boorjian SA, Weight CJ, Han LC, Hassan MH, Shippee ND, Knoedler JJ, Erwin PJ, Costello BA, Chow GK, Leibovich BC. Comparative effectiveness of partial and radical nephrectomy for localized renal tumors on survival and renal function: A systematic review and meta-analysis. *Journal of Urology* 2012;188(1):51-7.
21. **Kim SP**, Frank I, Weight CJ, Thapa P, Boorjian SA. The impact of squamous and glandular differentiation on survival following radical cystectomy for urothelial carcinoma. *Journal of Urology* 2012;188(2):405-9.
22. Weight CJ, **Kim SP**, Karnes RJ, Cheville JC, Leibovich BC. A prospective, controlled phase II study of neoadjuvant Exisulind therapy before radical prostatectomy: Effect on apoptosis. *Urology* 2012;80(2):17-22.
23. **Kim SP**, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JM, Tollefson MK, Frank I. Contemporary trends of in-hospital complications for radical cystectomy from a population-based analysis. *British Journal of Urology International* 2012;110(8):1163-8.
24. Knoedler JJ, Boorjian SA, **Kim SP**, Weight CJ, Thapa P, Tarrell RF, Cheville JC, Frank I. Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. *Journal of Urology* 2012;188(2):115-9.
25. Zarei S, Frank I, Boorjian SA, Thompson RH, **Kim S**, Weight C, Tarrell R, Thapa P, Cheville JC. Prognostic significance of measured depth of invasion of urothelial carcinoma of the bladder compared to the 2010 American Joint Committee on Cancer pT2 and pT3 classifications. *J Urol*. 2012 Nov;188(5):1706-11
26. Wang JK, Boorjian SA, Cheville JC, **Kim SP**, Tarrell RF, Thapa P, Frank I. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. *World J Urol*. 2012 Dec;30(6):801-6
27. Montori VM, **Kim SP**, Guyatt GH, Shah ND. Which design for which question? An exploration toward a translation table for comparative effectiveness research. *J Comp Eff Res*. 2012 May;1(3):271-9.

28. **Kim SP**, Crispen P, Thompson RH, Weight CJ, Boorjian SA, Costello B, Lohse CM, Leibovich BC. Assessment of the pathologic inclusion criteria from contemporary adjuvant trials predicting disease progression after nephrectomy for renal cell carcinoma. *Cancer* 2012;119(18):4112-20.
29. Wang JK, Boorjian SA, Cheville JC, **Kim SP**, Tarrell RF, Thapa P, Frank I. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: A matched cohort analysis. *World Journal of Urology* 2012;30(6):801-6.
30. Kaushik D, **Kim SP**, Childs A, Lohse CM, Costello BA, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. *European Urology* 2012 Oct; 64(4): 600-6.
31. **Kim SP**, Weight CJ, Shah ND, Boorjian SA, Tilburt JC, Han LC, Thompson RH, Trinh QD, Sun M, Moriarty JP, Karnes RJ. Disparities in access to hospitals with robotic surgery for prostate cancer patients undergoing radical prostatectomy. *Journal of Urology* 2013.189(2):514-20.
32. Ferwana M, Firwana B, Hasan R, Murad MH, Montori VM, **Kim SP**, Al-Mallah MH. Pioglitazone and risk of bladder cancer in patients with type-II diabetes mellitus: A meta-analysis of controlled studies. *Diabetic Medicine* 2013 Sep;30(9):1026-32.
33. **Kim SP**, Thompson RH. Partial nephrectomy and renal function. *Current Opinions in Urology*, 2013;23(2):105-11.
34. Smaldone MC, Churukanti G, Simhan J, **Kim SP**, Reyes J, Zhu F, Kutikov A, Viterbo R, Chen DY, Greenberg RE, Uzzo RG. Clinical characteristics associated with treatment type for localized renal tumors. Implications of practice pattern assessment. *Urology*, 2013 Feb;81(2):269-75.
35. Wang JK, Tollefson MK, **Kim SP**, Boorjian SA, Leibovich BC, Lohse CM, Cheville JC, Thompson RH. Iatrogenic splenectomy during nephrectomy for renal tumors. *International Journal of Urology*, 2013 Sep; 20(9): 896-902.
36. Trinh QD, Sun M, **Kim SP**, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, Shariat SF, Hu JC, Karakiewicz PI. The impact of hospital volume, residency, and fellowship training on perioperative outcomes. *Urologic Oncology: Seminars and Original Investigation*, 2014 Jan; 32(1):29.e13-20.
37. **Kim SP**, Shah ND, Weight CW, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. *British Journal of Urology* 2013 Aug; 112(4):478-84
38. **Kim SP**, Leibovich BC, Shah ND, Weight CJ, Borah B, Han LC, Boorjian SA, Thompson RH. The relationship of postoperative complications with in-hospital outcomes and costs after renal surgery for kidney cancer. *British Journal of Urology International* 2013, Apr;111(4):580-8.
39. Shuch B, Hanley J, Lai J, Vourganti S, **Kim SP**, Setodji CM, Dick AW, Chow WH, Saigal C; the Urologic Diseases in America Project. Overall survival advantage with partial nephrectomy: A bias of observational data. *Cancer* 2013, Aug 15; 119(16):2981-9.
40. Weight CJ, Crispen PL, Breau RH, **Kim SP**, Lohse CM, Boorjian SA, Thompson RH, Leibovich BC. Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urological Association surgeons. *British Journal of Urology International* 2013 May;111(5):731-8.
41. Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, Shariat SF, Larouche A, Tian Z, **Kim SP**, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh DQ, Sun M. Health care-associated infections after major cancer surgery: Temporal trends, patterns of care and effect on mortality. *Cancer*, 2013 Jun 15;119(12):2317-24
42. Sukumar S, Roghmann F, Trinh VQ, Sammon JD, Gervais MK, Tan HJ, Ravi P, **Kim SP**, Hu JC, Karakiewicz PI, Noldus J, Sun M, Trinh QD. National trends in hospital-acquired preventable adverse events after major cancer surgery in the U.S.A. *British Medical Journal* 2013 Jun 26;3(6).

43. **Kim SP**, Karnes RJ, Nguyen PL, Thompson RH, Ziegenfuss JY, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. *J Urol*. 2013 Jun;189(6):2092-8.
44. **Kim SP**, Tilburt JC, Karnes RJ, Ziegenfuss JY, Han LC, Shah ND, Frank I, Smaldone MC, Gross CP, Han LC, Yu JB, Trinh QD, Sun M, O'Malley RL, Nguyen PL. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. *Urology*, 2013 Oct;82(4):807-12
45. Weight CJ, **Kim SP**, Jacobson DJ, McGee ME, Boorjian SA, Thompson RH, Leibovich BC, Karnes RJ, St. Sauver J. The effect of benign lower tract symptoms on subsequent prostate cancer testing and diagnosis. *European Urology*, 2013 Jun;63(6):1021-7.
46. Knoedler J, Han L, Granberg C, Kramer S, Chow G, Gettman M, Kimball B, Moriarty J, **Kim SP**, Husmann D. Population-based comparison of laparoscopic and open pyeloplasty in paediatric pelvi-ureteric junction obstruction. *BJU Int*. 2013 Jun;111(7):1141-7
47. Thompson RH, Boorjian SA, **Kim SP**, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. *BJU Int*. 2014 May; 113(5b):E17-21.
48. Sun M, Sammon JD, Becker A, Roghmann F, Tian Z, **Kim SP**, Larouche A, Abdollah F, Hu JC, Karakiewicz PI, Trinh QD. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. *BJU Int*. 2014 Feb; 113(2):200-8.
49. Sukumar S, Roghmann F, Trinh VQ, Sammon JD, Gervais MK, Tan HJ, Ravi P, **Kim SP**, Hu JC, Karakiewicz PI, Noldus J, Sun M, Menon M, Trinh QD. National trends in hospital-acquired preventable adverse events after major cancer surgery in the USA. *BMJ Open*. 2013 Jun 26;3(6)
50. Ranasinghe W, **Kim SP**, Lawrentschuk N, Sengupta S, Hounscome L, Barber J, Jones R, Davis P, Bolton D, Persad R. Population based analysis of Prostate Specific Antigen (PSA) screening in younger men (<55 years) in Australia. *BJU Int*. 2014 Jan; 113(1):77-83.
51. **Kim SP**, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smaldone MC, Frank I, Gettman MT, Tollefson MK, Thompson RH. Hospitalization costs for radical prostatectomy attributable to robotic surgery. *European Urology* 2013, Jul;64(1):11-6.
52. Boorjian SA, **Kim SP**, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, Thapa P, Frank I. Comparative performance of comorbidity indices for estimating perioperative and 5-year all-cause mortality following radical cystectomy for bladder cancer. *Journal of Urology*, 2013 Jul;190(1):55-60.
53. Sammon JD, Ghani KR, Karakiewicz PI, Bhojani N, Ravi P, Sun, M, Sukumar S, Trinh VQ, Kowalczyk KJ, **Kim SP**, Peabody JO, Menon M, Trinh QD. Temporal trends, practice patterns, and treatment outcomes for infected upper urinary tract stones in the United States. *European Urology* 2013, Jul;64(1):85-92.
54. **Kim SP**, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. *BJU Int*. 2013 Aug;112(4):478-84
55. **Kim SP**, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A National Survey of Radiation Oncologists and Urologists on Recommendations of Prostate-Specific Antigen Screening for Prostate Cancer. *BJU Int*. 2014 May; 113(5b):E106-11.
56. Eisenberg MS, Thompson RH, Frank I, **Kim SP**, Cotter KJ, Tollefson MK, Kaushik D, Thapa P, Tarrell R, Boorjian SA. Long-Term Renal Function Outcomes After Radical Cystectomy. *J Urol*. 2014 Mar; 191(3):619-25.

57. Sammon J, Zhu G, Sood A, Sukumar S, **Kim SP**, Sun M, Karakiewicz PI, Menon M, Trinh QD, Elder JS. Pediatric Nephrectomy: Incidence, Indications and Utilization of Minimally Invasive Techniques. *J Urol*. 2014 Mar; 191(3):764-70.
58. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, **Kim SP**, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate*. 2014 Feb; 72(2):210-6.
59. Weight CJ, **Kim SP**, Jacobson DJ, McGree ME, Karnes RJ, St Sauver J. Men (Aged 40-49 Years) With a Single Baseline Prostate-specific Antigen Below 1.0 ng/ml Have a Very Low Long-term Risk of Prostate Cancer: Results From a Prospectively Screened Population Cohort. *Urology*. 2013 Dec; 82(6):1211-7.
60. Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, Shariat SF, Tian Z, **Kim SP**, Kowalczyk KJ, Hu JC, Menon M, Trinh QD. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. *JAMA Surg*. 2014 Jan;149(1):43-9.
61. Corcoran A, Handorf, E, Canter D, Tomaszewski J, Bekelman J, **Kim SP**, Uzzo R, Kutikov A, Smaldone MC. Variation in Performance of Candidate Surgical Quality Measures for Muscle Invasive Bladder Cancer by Hospital Type. *BJU Int* 2015 Feb; 115(2):230-7.
62. Svatek RS, Hollenbeck BK, Holmäng S, Lee R, **Kim SP**, Stenzl A, Lotan Y. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. *Eur Urol*. 2014 Aug;66(2):253-62.
63. Han LC, **Kim SP**, Gross CP, Ross JS, Van Houten HK, Smaldone MC, Krambeck AE, Shah ND. Association of physician specialty and medical therapy for benign prostatic hyperplasia. *Med Care*. 2014 Feb;52(2):128-36.
64. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, **Kim SP**, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate*. 2014 Feb;74(2):210-6.
65. Gandaglia G, Abdollah F, Hu J, **Kim SP**, Briganti A, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI, Trinh QD, Sun M. Is Robot-Assisted Radical Prostatectomy Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, Positive Surgical Margins, and Use of Additional Cancer Treatments. *J Endourol*. 2014 Jul;28(7):784-91.
66. Gandaglia G, Karakiewicz PI, Briganti A, Trinh Q, Schiffmann J, Tian Z, **Kim SP**, Nguyen PL, Graefen M, Montorsi F, Sun M, Abdollah F. Intensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study. *Ann Oncol*. 2014 May; 25(5):979-86.
67. **Kim SP**, Gross CP, Nguyen PY, Smaldone MC, Thompson RH, Shah ND, Kutikov A, Han LC, Karnes RJ, Ziegenfuss JY, Tilburt JC. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. *Prostate Cancer Prostatic Dis*. 2014 Jun;17(2):163-9.
68. Kardos SV, Gross CP, Shah ND, Schulam PG, Trinh QD, Smaldone MC, Sun M, Weight CJ, Sammon J, Han LC, **Kim SP**. Association of Type of Renal Surgery and Access to Robotic Technology for Kidney Cancer: Results From A Population-Based Cohort. *BJU Int*. 2014 Oct;114(4):549-54.
69. Tilburt JC, Kelley S, DeCourtney CA, Humeniuk KM, Latini J, **Kim SP**. Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers. *Int J Circumpolar Health*. 2014 Feb 27;73:23637.
70. Sammon JD, Zhu G, Sood A, Sukumar S, **Kim SP**, Sun M, Karakiewicz PI, Menon M, Trinh QD, Elder JS. Pediatric nephrectomy: incidence, indications and use of minimally invasive techniques. *J Urol*. 2014 Mar;191(3):764-70

71. Han LC, Delpé S, Shah ND, Ziegenfuss JY, Tilburt JC, Karnes RJ, Nguyen PL, Gross CP, Yu JB, Trinh QD, Sun M, Ranasinghe WK, **Kim SP**. Perceptions of Radiation Oncologists and Urologists on Sources and Type of Evidence to Inform Prostate Cancer Treatment Decisions. *Int J Radiat Oncol Biol Phys*. 2014 Jun 1;89(2):277-83.
72. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, Shariat SF, **Kim SP**, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg*. 2014 Apr;57(2):82-8.
73. Gandaglia G, Sammon JD, Chang SL, Choueiri TK, Hu JC, Karakiewicz PI, Kibel AS, **Kim SP**, Konijeti R, Montorsi F, Nguyen PL, Sukumar S, Menon M, Sun M, Trinh QD. Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. *J Clin Oncol*. 2014 May 10;32(14):1419-26.
74. Mahal BA, Ayal AA, Ziehr DR, Hyatt A, Sammon J, Schmidt M, Choueiri TK, Hu JC, Sweeney CJ, Beard C, D'Amico AV, Martin NE, **Kim SP**, Trinh QD, Nguyen PL. Trends in disparate treatment of African-American men with localized prostate cancer across NCCN risk groups. *Urology*. 2014 Aug; 84(2):386-92.
75. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, **Kim SP**, Trinh QD, Nguyen PL. Racial disparities in prostate cancer specific mortality in men with low-risk prostate cancer. *Clinical Genitourinary Cancer* 2014 Oct; 12(5):e189-95.
76. **Kim SP**, Gross CP, Nguyen PL, Smaldone MC, Shah ND, Karnes RJ, Thompson RH, Han LC, Yu JB, Trinh QD, Ziegenfuss JY, Sun M, Tilburt JC. Perceptions of active surveillance and treatment recommendations for low-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. *Med Care*. 2014 Jul;52(7):579-8
77. Aizer AA, Chen MH, Parekh A, Choueiri TK, Hoffman KE, **Kim SP**, Martin NE, Hu JC, Trinh QD, Nguyen PL. Refusal of curative radiation therapy and surgery among patients with cancer. *Int J Radiat Oncol Biol Phys* 2014, Jul 15;89(4):756-64.
78. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Lathan C, **Kim SP**, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. *Urol Oncol*. 2014 Nov; 32(8):1285-91.
79. Becker A, Ravi P, Roghmann F, Trinh QD, Tian Z, Larouche A, **Kim S**, Shariat SF, Kluth L, Dahlem R, Fisch M, Graefen M, Eichelberg C, Karakiewicz PI, Sun M. Laparoscopic Radical Nephrectomy vs Laparoscopic or Open Partial Nephrectomy for T1 Renal Cell Carcinoma: Comparison of Complication Rates in Elderly Patients During the Initial Phase of Adoption. *Urology*. 2014 Jun;83(6):1285-93.
80. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, **Kim SP**, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. *J Geriatr Oncol*. 2014 Oct 1;5(4):352-8.
81. Sammon JD, Pucheril D, Abdollah F, Varda B, Sood A, Bhojani N, Chang SL, **Kim SP**, Ruhotina N, Schmid M, Sun M, Kibel AS, Menon M, Semel ME, Trinh QD. Preventable Mortality Following Common Urologic Surgery: Failing to Rescue? *BJU Int*. 2015 Apr; 115(4):666-74.
82. Wang SY, Wang R, Yu JB, Ma X, Xu X, **Kim SP**, Soulos PR, Saraf A, Gross CP. Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care. *Med Care*. 2014 Aug;52(8):680-7.
83. Gandaglia G, Karakiewicz P, Briganti A, Trudea V, Trinh QD, **Kim SP**, Montorsi F, Nguyen PL, Sun M. Early radiotherapy after radical prostatectomy improves cancer-specific survival in patients with highly aggressive prostate cancer. *Int Journal of Urology*. 2015 Jan; 22(1):89-95.

84. Sammon JD, Klett DE, Sood A, Olugbade K, Schmid M, **Kim SP**, Menon M, Trinh QD. Sepsis after major cancer surgery. *J Surg Res*. 2015 Feb; 193(2):788-94.
85. Maroongroge S, Dosoretz AP, **Kim SP**, Gross CP, Yu JB. Revisiting the SGR “Hole”: Sources of healthcare cost stabilization in 2010-2012. *Int J Radiat Oncol Biol Phys*. 2014 Dec 1; 90(5):983-5.
86. **Kim SP**, Gross CP, Smaldone MC, Han LC, Lotan Y, Svatek RS, Thompson RH, Karnes RH, Trinh QD, Kutikov A, Shah ND. Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: Results from a privately insured patient population. *Pros Cancer and Prostatic Disease*. 2015 Mar; 18(1):13-7.
87. Wang E, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, **Kim SP**. Variation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach. Results from the National Cancer Database. *J Urol*. 2015 Mar; 193(3):820-5.
88. Smaldone MC, Handorf E, **Kim SP**, Thompson RH, Costello BA, Corcoran AT, Wong YN, Uzzo RG, Leibovich BC, Kutikov A, Boorjian SA. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. *J Urol*. 2015 Apr; 193(4):1108-13.
89. Wang EH, Gross CP, Tilburt JC, Yu JB, Nguyen PL, Smaldone MC, Shah ND, Abouassaly R, Sun M, **Kim SP**. Shared decision-making and use of decision aids for localized prostate cancer: perceptions from radiation oncologists and urologists. *JAMA Internal Medicine* 2015 May; 175(5):792-9.
90. Wang EH, Yu JB, Gross CP, Abouassaly R, Cherullo EC, Smaldone MC, Shah ND, Kiechle J, Trinh QD, Sun M, **Kim SP**. Association between surgeon and hospital characteristics and lymph node counts from radical prostatectomy and pelvic lymph node dissection. *Urology* 2015 April; 85(4):890-5.
91. Hyder JA, Roy N, Wakeam E, Hernandez R, **Kim SP**, Bader AM, Cima RR, Nguyen LL. Performance measurement in surgery through the national quality forum. *J Am Coll Surg* 2014 Nov; 219(5):1037-46.
92. Psutka SP, **Kim SP**, Gross CP, Van Houten H, Thompson RH, Abouassaly R, Weight CJ, Boorjian SA, Leibovich BC, Shah ND. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. *Urology*. 2015 Feb; 85(2): 442-50.
93. Maurice MJ, Abouassaly R, **Kim SP**, Zhu H. Contemporary nationwide patterns of active surveillance use for prostate cancer. *JAMA Internal Medicine* 2015 Sep; 175(9):1569-71.
94. Hwang J, Minnillo B, **Kim SP**, Abouassaly R. Assessment of healthcare quality metrics: length of stay, 30-day readmission, and 30-day mortality for radical nephrectomy with inferior vena cava thrombectomy. *Can Urol Assoc J*. 2015 Mar-Apr; 9(3-4):114-21.
95. Maroongroge S, **Kim SP**, Mougalian S, Johung K, Decker RH, Soulos PR, Long JB, Gross CP, Yu JB. The costs of cancer-related physician services to Medicare. *Yale J Bio Med*. 2015 June 1; 88(2):107-14.
96. Sammon JD, Abdollah F, Reznor G, Pucheril D, Choueiri TK, Hu JC, **Kim SP**, Schmid M, Sood A, Sun M, Kibel AS, Nguyen PL, Menom M, Trinh QD. Patterns of declining use and the adverse effect of primary androgen deprivation therapy on all-cause mortality in elderly men with prostate cancer. *Eur Urol* 2015 Jul; 68(1):32-9.
97. Ranasinghe WK, **Kim SP**, Papa NP, Sengupta S, Frydenberg M, Bolton D, Pond D, Ried K, Marshall MJ, Persad R, Lawrenstuck N. Prostate cancer screening in primary health care: The current state of affairs. *Springerplus* 2015 Feb 13; 4:78.
98. Tabayoyong W, Abouassaly R, Kiechle J, Cherullo EE, Meropol NJ, Shah ND, Dong S, Thompson RH, Smaldone MC, Zhu H, Ialucci S, **Kim SP**. Variation in surgical margin status by

- surgical approach among patients undergoing partial nephrectomy for small renal masses. *J Urol* 2015 Dec; 194(6):1548-53.
99. Maurice MJ, Abouassaly R, **Kim SP**, Zhu H. Contemporary nationwide patterns of active surveillance use for prostate cancer. *JAMA Intern Med.* 2015 Sep; 175(9):1569-71.
 100. Maurice MJ, Zhu H, Kiechle JE, **Kim SP**, Abouassaly R. Nonclinical factors predict selection of initial observation for renal cell carcinoma. *Urology* 2015 Nov; 86(5):892-9.
 101. Maurice MJ, Zhu H, **Kim SP**, Abouassaly R. Increased use of partial nephrectomy to treat high-risk disease. *BJU Int.* 2016 Jun; 117(6B):E75-86.
 102. Kiechle JE, Abouassaly R, Smaldone MC, Shah ND, Dong S, Cherullo EE, Nakamoto D, Zhu H, Cooney MM, **Kim SP**. National trends of local ablative therapy among young patients with small renal masses in the United States. *Urology* 2015 Nov;86(5):962-7.
 103. Maurice MJ, Zhu H, Kiechle JE, **Kim SP**, Abouassaly R. Increasing biopsy utilization for renal cell carcinoma is closely associated with treatment. *Urology* 2015 Nov; 86(5):906-13.
 104. Maurice MJ, Zhu H, Kiechle JE, **Kim SP**, Abouassaly R. Comorbid disease burden is independently associated with higher-risk disease at prostatectomy in patients eligible for active surveillance. *J Urol* 2015 Apr; 195(4 Pt 1): 919-24.
 105. Purcheril D, Sammon JD, Sood A, Abdollah F, Choueiri TK, Meyer C, Hanske J, **Kim SP**, Nguyen PL, Kibel AS, Weissman JS, Menon M, Trinh QD. Contemporary nationwide patterns of self-reported prostate-specific antigen in U.S. Veterans. *Urol Onc* 2015 Dec; 33(12):503.e7-15.
 106. Maurice MJ, Zhu H, **Kim SP**, Abouassaly, R. Re-examining the association between positive surgical margins and survival after partial nephrectomy in a large American cohort. *J Endourol* 2016 Jun; 30(6):698-703.
 107. Chao, Krishna N, Aizer AA, Dalela D, Hanske J, Li H, Meyer CP, **Kim SP**, Mahal BA, Reznor G, Schmid M, Choueiri TK, O'Leary M, Trinh QD. Asian Americans and prostate cancer: A nationwide population-based analysis. *Urol Oncol* 2016 May; 34(5):233.e7-15.
 108. Kiechle JE, Abouassaly R, Gross CP, Dong S, Cherullo EE, Zhu H, Trinh DQ, Meropol NJ, Hoimes, **Kim SP**. Racial disparities in partial nephrectomy persist across hospital type. Results from a population-based cohort. *Urology* 2016 Apr; 90:69-74.
 109. Maurice MJ, Zhu H, **Kim SP**, Abouassaly R. Robotic prostatectomy is associated with increased patient travel and treatment delay. *Can Urol Assoc J.* 2016 May- Jun; 10(5-6):192-201.
 110. **Kim SP**, Abouassaly R. Improving the patient experience in the delivery of high quality surgical care and health outcomes. *Cancer* 2016 Aug 15; 122(16):2457-8.
 111. **Kim SP**, Abouassaly R. Treatment of Patients with Positive Margins after Partial Nephrectomy. *J Urol.* 2016 Aug; 196(2):301-2.
 112. Wang EH, Yu JB, Abouassaly R, Meropol NJ, Cooper G, Shah ND, Williams SB, Gonzalez C, Smaldone MC, Kutikov A, Zhu H, **Kim SP**. Disparities in treatment of prostate cancer with high-risk prostate cancer: Results from a population-based cohort. *Urology* 2016 Sep; 95:88-94.
 113. Maurice MJ, **Kim SP**, Abouassaly R. Current Status of Prostate Cancer Diagnosis and Management in the United States. *JAMA Oncol.* 2016 Nov 1;2(11):1505-1507.
 114. Lester-Coll NH, Park HS, Rutter CE, Corso CD, Mancini BR, Yeboa DN, **Kim SP**, Gross CP, Yu JB. The Association Between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-risk Prostate Cancer. *Urology* 2016 Oct; 96:128-135.
 115. Slopnick EA, **Kim SP**, Kiechle JE, Gonzalez CM, Zhu H, Abouassaly R. Racial Disparities Differ for African Americans and Hispanics in the Diagnosis and Treatment of Penile Cancer. *Urology* 2016 Oct; 96:22-28.
 116. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, **Kim SP**, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer

centers perform better than community cancer centers? *Cancer* 2016 Nov 15; 122(21):3371-3377.

117. **Kim SP**, Karnes RJ, Gross CP, Meropol NJ, Van Houten H, Abouassaly R, Shah ND. Contemporary national trends of prostate cancer screening among privately insured men in the United States. *Urology* 2016 Nov; 97:111-117.
118. Maurice MJ, Bream MJ, **Kim SP**, Abouassaly R. Surgical quality of minimally invasive adrenalectomy for adrenocortical carcinoma: a contemporary analysis using the National Cancer Database. *BJU Int.* 2017 Mar; 119(3):436-443.
119. Slopnick EA, Hijaz AK, Nguyen CT, Abouassaly R, Gonzalez CM, Mahajan ST, Henderson JW, Bream MJ, **Kim SP**. National Surgical Trends and Perioperative Outcomes of Mid-Urethral Sling Placement for Stress Urinary Incontinence. *Urology* 2017 Jan; 99:57-61.
120. Maurice MJ, **Kim SP**, Abouassaly R. Socioeconomic status is associated with urinary diversion utilization after radical cystectomy for bladder cancer. *Int Urol Nephrol.* 2017 Jan; 49(1):77-82.
121. Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, **Kim SP**, Malhotra A, Handorf E, Wong YN, Uzzo RG, Kutikov A. Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. *Med Care.* 2016 Nov 4. [Epub ahead of print]
122. **Kim SP**, Gross CP, Meropol N, Kutikov A, Smaldone MC, Shah ND, Yu JB, Psutka S, Kiechle J, Abouassaly R. National treatment trends among older patients with T1-localized renal cell carcinoma. *Urol Oncol.* 2017 Mar; 35(3):113.e15-113.e21
123. Gershman B, Van Houten HK, Herrin J, Moreira DM, **Kim SP**, Shah ND, Karnes RJ. Impact of prostate-specific antigen (PSA) screening trials and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications. *Eur Urol.* 2017 Jan; 71(1):55-65.
124. Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LM, **Kim SP**, Hoffman KE, Giordano SH, Chapin BF. Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. *Cancer.* 2017 May 1; 123(9): 1617-1624.
125. Gershman B, Meier SK, Jeffrey MM, Moreira DM, Tollefson MK, **Kim SP**, Karnes RJ, Shah ND. Re-defining and contextualizing the hospital volume-outcome relationship for robotic-assisted radical prostatectomy: implications for centralization of care. *J Urol.* 2017 Jan 30 [Epub ahead of print]
126. Campbell RA, Slopnick EA, Ferry EK, Zhu H, **Kim SP**, Abouassaly R. Disparity between pre-existing management of penile cancer and NCCN guidelines. *Urol Oncol.* 2017 Mar 28. Pii: S1078-1439(17)30102-3.
127. Smaldone MC, Egleston B, Hollingsworth JM, Hollenbeck BK, Miller DC, Morgan TM, **Kim SP**, Malhotra A, Handorf E, Wong YN, Uzzo RG, Kutikov A. Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data. *Med Care.* 2017 Apr; 55(4): 398-404.
128. Minnillo BJ, Tabayoyong W, Francis JJ, Maurice MJ, Zhu H, **Kim SP**, Abouassaly R. Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival. *Can Urol Assoc J.* 2017 May; 11(5):E184-E191.
129. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, **Kim SP**, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. *Ann Oncol.* 2017 May 1; 28(5):1098-1104.
130. Lawson KA, Saarela O, Abouassaly R, **Kim SP**, Breau RH, Finelli A. The impact of quality variations on patients undergoing surgery for renal cell carcinoma: a national cancer database study. *Eur Urol.* 2017 Sep; 72(3):379-386.

131. Williams SB, Huo J, Dafashy TJ, Ghaffary CK, Baillageon JG, Morales EE, **Kim SP**, Kuo YF, Orihuela E, Tyler DS, Freedland SJ, Kamat AM. Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment. *Urol Oncol*. 2017 Jun 21. Pii:S0178-1439(17)30252-1.
132. Gershman B, Meier SK, Jeffery MM, Moreira DM, Tollefson MK, **Kim SP**, Karnes RJ, Shah ND. Redefining and contextualizing the hospital volume-outcome relationship for robot-assisted radical prostatectomy: implications for centralization of care. *J Urol*. 2017 Jul; 198(1):92-99.
133. **Kim SP**, Campbell SC, Gill I, Lane BR, Van Poppel H, Smaldone MC, Volpe A, Kutikov A. Collaborative review of risk benefit trade-offs between partial and radical nephrectomy in the management of anatomically complex renal masses. *Eur Urol*. 2017 Jul; 72(1):64-75.
134. Williams SB, Huo J, Kosarek CD, Chamie K, Rogers SO Jr, Williams MA, Giordano SH, **Kim SP**, Kamat AM. Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. *Cancer Causes Control*. 2017 Jul; 28(7):755-766.
135. **Kim SP**, Tilburt JC, Boughey JC. Interventions to promote better conversations about initial treatment for prostate cancer. *Bull Am Coll Surg*. 2017 May; 102(5):48-9.
136. Williams SB, Huo J, Chu Y, Baillargeon JG, Daskivich T, Kuo YF, Kosarek CD, **Kim SP**, Orihuela E, Tyler DS, Freedland SJ, Kamat AM. Cancer and all-cause mortality in bladder cancer patients undergoing radical cystectomy: development and validation of a nomogram to treatment decision-making. *Urology*. 2017 Dec;110:76-83. Epub 2017 Aug 25.
137. Weight CJ, Narayan VM, Smith D, **Kim SP**, Karnes RJ. The effects of beginning population based PSA screening at age 40. *Urology*. 2017 Dec;110:127-133. Epub 2017 Aug 24.
138. Chen VS, Abouassaly R, Gonzalez CM, Kutikov A, Smaldone MC, Meropol NJ, Psutka SP, Williams SB, O'Malley R, Sedlacek HM, **Kim SP**. Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: results from a population-based cohort. *Urol Oncol*. 2017 Nov; 35(11):662.e17-662.e21. Epub 2017 Aug 7.
139. Bhindi B, Wallis CJD, Boorjian SA, Thompson RH, Farrell A, **Kim SP**, Karam JA, Capitanio U, Golijanin D, Leibovich BC, Gershman B. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. *BJU Int*. 2018 May; 121(5):684-698.
140. Slopnick EA, Hijaz AK, Henderson JW, Mahajan ST, Nguyen CT, **Kim SP**. Outcomes of minimally invasive abdominal sacrocolpopexy with resident operative involvement. *Int Urogynecol J*. 2018 Feb 20. [Epub ahead of print]
141. Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, **Kim SP**, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB. Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. *Cancer*. 2018 Aug 1; 124(15):3127-3135.
142. Sedlacek HM, Kim AH, **Kim SP**. Advancing the quality of care for newly diagnosed prostate cancer patients: novel uses of patient-reported outcomes. *Ann Surg Oncol*. 2018 Jun; 25(6):1475-1477.
143. Kim AH, Konety B, Chen Z, Schumacher F, Kutikov A, Smaldone M, Abouassaly R, Khanna A, **Kim SP**. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer. *Urology*. 2018 Jul 7. pii: S0090-4295(18)30630-7. [Epub ahead of print]
144. Pacyna JE, **Kim S**, Yost K, Sedlacek H, Petereit D, Kaur J, Rapkin B, Grubb R, Paskett E, Chang GJ, Sloan J, Basch E, Major B, Novotney P, Taylor J, Buckner J, Parsons JK, Morris M, Tilburt JC. The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD. *BMC Cancer*. 2018 Aug 6; 18(1):788.

145. **Kim SP**, Meropol NJ, Gross CP, Tilburt JC, Konety B, Yu JB, Abouassaly R, Weight CJ, Williams SB, Shah ND. Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists. *Urol Oncol*: S1078-1439(18)30250-3. Epub 2018 Sep 3.
146. Khanna A, Yerram N, Zhu H, **Kim S**, Abouassaly R. Utilization of BCG for Non-Muscle Invasive Bladder Cancer in an Era of BCG Supply Shortages. *Urology*. 2018 Sep 3. Pii: S0090-4295(18)30951-8. [Epub ahead of print]
147. Bukavina L, Tilburt JC, Konety B, Shah ND, Gross CP, Yu JB, Schumacher F, Kutikov A, Smaldone MC, **Kim SP**. Perceptions of Prostate MRI and Fusion Biopsy of Radiation Oncologists and Urologists for Patients Diagnosed with Prostate Cancer: Results from a National Study. *Eur Urol Focus*. 2018 Sep 12. Pii: S2405-4569(18)30256-6. [Epub ahead of print]
148. Slopnick EA, Petrikovets A, Sheyn D, **Kim SP**, Nguyen CT, Hijaz AK. Surgical Trends and Patient Factors Associated with the Treatment of Apical Pelvic Organ Prolapse from a National Sample. *Int Urogynecol J*. 2018 Oct 3. [Epub ahead of print]
149. Slopnick EA, Petrikovets A, Sheyn A, **Kim SP**, Nguyen CT, Hijaz A. Surgical trends and patient factors associated with the treatment of apical pelvic organ prolapse. *Int Urogynecol* 2018 Oct 3.
150. **Kim SP**, Gross CP, Shah ND, Tilburt JC, Konety B, Williams SB, Weight CJ, Yu JB, Kumar AMS, Meropol NJ. Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. *Ann Surg Oncol*. 2018 Oct 11. [Epub ahead of print]
151. Gershman B, Bukavina L, Chen Z, Konety B, Schumacher F, Li L, Kutikov A, Smaldone M, Abouassaly R, **Kim SP**. The Association of Robot-assisted versus Pure Laparoscopic Radical Nephrectomy with Perioperative Outcomes and Hospital Costs. *Eur Urol Focus*. 2018 Oct 22. [Epub ahead of print]
152. Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, **Kim SP**. A national survey of radiation oncologist and urologists on prediction tools and nomograms for localized prostate cancer. *World Journal of Urology* 2019 Jan 22 (Epub ahead of print).
153. Gershman B, Leibovich BC, **Kim SP**. Partial versus radical nephrectomy for clinical T1a Renal Mass. *Eur Urol Focus* 2019 Feb. 15 (Epub ahead of print).
154. **Kim SP**, Tilburt JC, Shah ND, Konety B, Nguyen PL, Abouasally R, Williams SB Gross CP. A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-risk Prostate Cancer. *Clin Genitourin Cancer* 2019 Feb 7.
155. Sathianathen NJ, Kwaan M, Lawrentschuk N, Weight CJ, **Kim SP**, Murphy DG, Moon DA, Konety BR. Adverse impact of malnutrition markers on major abdominopelvic cancer surgery. *ANZ J Surg* 2019 Apr 8.
156. Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Bailargeon K, Klassen Z, Kulkarni GS, **Kim SP**, Lee EK, Holzbeirlein JM, Hollebecq BK, Gore JL. Systematic review of factors associated with the utilization of radical cystectomy for bladder cancer. *Eur Urol Oncol* 2019 Mar;2(2):119-125
157. **Kim SP**, Shah ND, Meropol NJ, Tilburt JC, Nguyen PL, Yu JB, Abouassaly R, Kim A, Gross CP. Recommendations of active surveillance for intermediate-risk prostate cancer: Results from a national survey of radiation oncologists and urologists. *Eur Urol Oncol* 2019 March;2(2):189-195.
158. Owens OL, **Kim SP**, Tavakoli AS. Are decision aids leading to shared prostate cancer decisions among African-American men? *iDecide. Cancer Causes Control* 2019 Jul;30(7):713-719.

159. Al-Alao O, Mueller-Leonhard C, **Kim SP**, Amin A, Tucci C, Kott O, Mega A, Golijanin D, Gershman B. Clinically node positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Clinical outcomes and development of a postoperative risk stratification model. *Urol Oncol* 2019 Oct 5.
160. Sathianan NK, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, **Kim SP**, Konety BR. A cost effectiveness analysis of systematic therapy for metastatic hormone-sensitive prostate cancer. *Eur Urol Oncol* 2019 Nov;2(6):649-655.
161. Pelcovits A, Mueller-Leonhard C, Mega A, Amin A, **Kim SP**, Golijanin D, Gershman B. Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Implications for multimodal management. *World J Urol* 2020 May;38(5):1243-1252.
162. Al-Alao O, Mueller-Leonhard C, **Kim SP**, Amin A, Tucci C, Kott O, Mega A, Golijanin D, Gershman B Clinically Node-Positive (cN+) Urothelial Carcinoma of the Bladder Treated With Chemotherapy and Radical Cystectomy: Clinical Outcomes and Development of a Postoperative Risk Stratification Model. *Urol Oncol* 2020 Mar;38(3):76e.19-76.e28
163. Matula JT, Tabayoyong W, Duplisea JJ, Chang S, Gore JL, Holzbeilein JM, KarshLI, **Kim SP**, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of non-muscle invasive among Society of Urologic Oncology (SUO) member. *Urol Oncol* 2020 May 16:S1078-1439(20)30181-2. doi: 10.1016/j.urolonc.2020.04.026. Online ahead of print.PMID: 324302
164. Ghabili K, Park HS, Yu JB, Sprenkle PC, **Kim SP**, Nguyen KA, Ma X, Gross CP. National trends in the management of patients with positive surgical margins at radical prostatectomy. *World J Urol.* 2020 Jun 19. doi: 10.1007/s00345-020-03298-6. Online ahead of print.PMID: 32562045
165. Bongiovanni T, **Kim SP**, Kim A, Kilelea B, Gross CP. Is there variation in private payor payments to cancer surgeons? *BMJ Open* Oct 5;10(10): e0354438
166. Gleisner AL, Moss A, Friedman Suresh K, Grunwald G, Torphy RJ, Colborn K, Ahrendt G, Tevis S, Christina N, Abud VL, de Araujo TB, Beaty LE, Thieu D, Glorioso TJ, **Kim SP**, Daughter S. De-implementation of axillary lymph node dissection in women with breast cancer is largely driven by site-level contextual effects. *Ann Surg* 2020.Dec18
167. Ghabill K, Park HS, Yu JB, Sprenkle PC, **Kim SP**, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margin at radical Prostatectomy. *World J Urol* 2020 June 19
168. Puneet K, Tilburt JC, Volk RJ, Bennett CL, Qureshi Z, Gershman B, Sedlacek H, **Kim SP**. Do radiation oncologists and urologists endorse decision aids for active surveillance of low-risk prostate cancer? *Eur J Cancer Care* 2021 Jan;30(1).
169. Dewitt-Foy M, Gam K, Modlin C, **Kim SP**, Abouasally R. Race, decisional regret and prostate cancer beliefs: Identifying targets to reduce racial disparities in prostate cancer. *J Urol* 2021 Feb; 205(2):425-433.
170. Rodrigues-Pessoa R, Morrison JC, Konety B, Gershman B, Cost N, Flaig T, Kessler E, Sharma P, **Kim SP**. National trends in clinical and pathologic stage for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. *Uro Onc: Seminars and Original Investigation*, 2021 in press.
171. Rodrigues-Pessoa R, Mueller A, Boxley P, Flaig T, Piper C, Konety B, Yu JH, Gershman B **Kim SP**. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle Invasive bladder cancer. *Uro Onc: Seminars and Original Investigation*, 2021 in press.

Chapters, Books, and Reviews

172. **Kim SP**, Thompson RH. Approach to the small renal mass—To treat or not to treat? *Urology Clinics of North America* 2012;39(2):171-9.
173. Campbell, Steven C, and Brian I. Rini. **Kim SP** and Leibovich, Bradley, *Renal Cell Carcinoma: Clinical Management*. New York: Humana Press, 2013; 3:43-52
174. Myldo, Jack. Prostate Cancer: Science and Practice, Academy Press 2015. Kieckle J, **Kim SP**. Prostate cancer prevention: Strategies and prevention.
175. Agrawal S, Sedlacek H, **Kim, SP**. Comparative Effectiveness of Surgical Treatments for Small Renal Masses. *Urology Clinics of North America*. 2017 May; 44(2): 257-267.
176. Ristau BT, **Kim SP**, Smaldone MC. Prostate cancer localized and locally advances. AUA Core Curriculum 2018
(<https://university.auanet.org/modules/webapps/core/index.cfm#/corecontent/223>)
177. Ristau BT, **Kim SP**, Smaldone MC. Prostate cancer localized and locally advances. AUA Core Curriculum 2019
(<https://university.auanet.org/modules/webapps/core/index.cfm#/corecontent/223>)
178. **Kim SP**, Maroni P, Rais-Baharmi S, Salami S. Prostate cancer screening and risk stratification. AUA Core Curriculum 2019
(<https://university.auanet.org/modules/webapps/core/index.cfm#/corecontent/74>)
179. Ristau BT, **Kim SP**, Smaldone MC. Prostate cancer localized and locally advances. AUA Core Curriculum 2020
(<https://university.auanet.org/modules/webapps/core/index.cfm#/corecontent/223>)

Peer Reviewed Editorials or Educational Materials

180. **Kim SP**, Thompson RH. Sunitinib prior to planned cytoreductive nephrectomy: Is this the new litmus test for metastatic renal cell carcinoma. *European Urology* 2011;60(3):455-6.
181. **Kim SP**, Thompson RH. Competing-risks analysis for renal cell carcinoma: how do we accurately communicate the risks and benefits of treatment to patients. *European Urology* 2011;60(6):1162.
182. **Kim SP**, Karnes RJ. Standard or extended lymphadenectomy in radical cystectomy: What is the metric of surgical quality for lymph node dissection that matters in improving patient outcomes? *European Urology* 2011;60(5):953-4.
183. **Kim SP**, Karnes RJ. A response to the USPTF: Prostate cancer screening: The case for patient-centered shared decision-making. *Journal of Men's Health* 2012;9(2):5-8.
184. Goldfarb R, Adejoro O, Lane B, **Kim SP**, Weight C. Re: Positive Surgical Margins in Robot-Assisted Partial Nephrectomy: A Multi-Institutional Analysis of Oncologic Outcomes (Leave No Tumor Behind): A. Khalifeh, J. H. Kaouk, S. Bhayani, C. Rogers, M. Stifelman, Y. S. Tanagho, R. Kumar, M. A. Gorin, G. Sivarajan, D. Samarasekera and M. E. Allaf *J Urol* 2013;190:1674-1679. *J Urol*. 2014 Apr 14
185. Maroongroge S, Dosoretz AP, **Kim SP**, Gross CP, Yu JB. Revisiting the sustainable growth rate “hole”: sources of healthcare cost stabilization in 2010-2012. *Int J Radiat Oncol Biol Phys* 2014 Dec 1.
186. Qureshi ZP, **Kim SP**, Bennett CL. Editorial comment. *Urology* 2019 Jan 12
187. Morrison JC, Gershman B, Konety B, **Kim SP**. Centralization of health care to facilitate greater use of nephron-sparing surgery for localized renal tumors: Identifying appropriate health care delivery. *Ann Surg Oncol* 2020 Jun;27(6):1735-36.

Invited Editorials and Commentaries

188. Weight CJ, **Kim SP**. Reply. *Urology*. 2013 Oct 19.

189. **Kim SP**, Thompson RH. Challenges and changes for locally advanced upper tract urothelial carcinoma. *European Urology* 2012;62(2):232-3.
190. Eisenberg MS, Leibovich BC, **Kim SP**. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. *Cancer*, 2013 Aug 15;119(16):3100
191. Eisenberg MS, Leibovich BC, **Kim SP**. Re: Phillip J. Gray, Stacey A. Fedewa, William U. Shipley, et al. Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base. *Eur Urol* 2013;63:823-9. *Eur Urol*. 2013 Jul 2.
192. **Kim SP** and Smaldone MC. The Role of Radical Prostatectomy and Lymph Node Dissection in the Treatment of Young Men With High-Grade Node-Positive Prostate Cancer: There May Be No RCTS—but There Are Good Reasons to Include Surgery. *Oncology* June 2014: 390+. Print.
193. **Kim SP**, Smaldone MC. Is a minimally invasive approach the solution for reducing surgical site infections. *JAMA Surgery*. 2014 Aug 20.
194. **Kim SP**, Tilburt JC, Boughey JC. Interventions to promote better conversations about initial treatment for prostate cancer. *Bull Am Coll Surg*. 2017 May;102(5):48-9.
195. Bukaniva L, Abouassaly R, **Kim SP**. Editorial Comment. *Urology*. 2017 Jun; 104:129-130.
196. Kim AH, **Kim SP**. Surviving travel or travelling to survive: the association of travel distance with survival in muscle invasive bladder cancer. *Transl Androl Urol*. 2018 Mar;7(Suppl 1): S83-S85.
197. Pessoa-Rodrigues R, Cherullo EE, **Kim SP**. Aligning reimbursement to improve outcomes for bladder cancer patients undergoing radical cystectomy. *Urology* 2020, in press.